# Clinical Cases: Cardiovascular Pharmacology

## Case 1: Digoxin Toxicity - Na+/K+-ATPase Inhibition

### Clinical Image
![Digoxin Toxicity ECG](case_01_image.jpg)
*Source: [Wikimedia Commons - Digoxin effect ECG](https://commons.wikimedia.org/wiki/File:Digoxin_toxicity_ECG.svg) - CC BY-SA 3.0*

### Patient Presentation
A 78-year-old woman is brought to the emergency department by her family after 2 days of nausea, vomiting, confusion, and visual disturbances. She describes seeing yellow-green halos around lights and everything looks "yellowish." She has atrial fibrillation and heart failure and was recently started on a new medication for a urinary tract infection.

### Demographics
- Age: 78 years
- Sex: Female
- Past Medical History: Atrial fibrillation, HFrEF (EF 35%), CKD stage 3 (baseline Cr 1.6)
- Medications: Digoxin 0.125 mg daily, lisinopril, carvedilol, furosemide, and newly started clarithromycin for UTI

### Chief Complaint
Nausea, vomiting, confusion, and yellow-tinged vision

### Physical Examination
- Blood pressure: 102/64 mmHg
- Heart rate: 42 bpm (markedly bradycardic)
- Temperature: 36.8°C
- General: Confused, appears ill
- Cardiovascular: Bradycardic, irregularly irregular rhythm with long pauses
- Neurological: Disoriented to time and place, no focal deficits
- Pupils: Normal

### Workup
- Serum digoxin level: 3.6 ng/mL (toxic; therapeutic 0.8-2.0 ng/mL)
- Serum potassium: 5.8 mEq/L (elevated)
- Serum creatinine: 2.4 mg/dL (worsened from baseline 1.6)
- ECG: Atrial fibrillation with complete heart block and slow junctional escape rhythm (40 bpm), frequent PVCs with coupling, "scooped" ST segments (digoxin effect)
- Additional findings: Bidirectional ventricular tachycardia noted transiently

### Diagnosis
Severe Digoxin Toxicity precipitated by:
1. Drug interaction with clarithromycin (P-glycoprotein inhibitor, increases digoxin levels)
2. Acute kidney injury (decreased digoxin clearance)

### Treatment
1. **Discontinue digoxin immediately**
2. **Digoxin-specific antibody fragments (DigiFab)** for:
   - Life-threatening arrhythmias (complete heart block, ventricular arrhythmias)
   - Potassium >5.5 mEq/L
3. Cardiac monitoring in ICU
4. Avoid calcium administration (can worsen digoxin toxicity)
5. Treat hyperkalemia if severe (insulin/glucose, not calcium)
6. Temporary pacing if symptomatic bradycardia persists
7. Discontinue clarithromycin
8. Review and adjust future digoxin dosing based on renal function

### Physiological Principles Demonstrated
- **Digoxin mechanism**: Digoxin inhibits the Na+/K+-ATPase, increasing intracellular sodium. This reduces the gradient driving the Na+/Ca2+ exchanger, leading to increased intracellular calcium and enhanced contractility.
- **Toxicity mechanism**: Excessive inhibition causes calcium overload, leading to delayed afterdepolarizations and triggered arrhythmias. Hyperkalemia further inhibits the Na+/K+-ATPase, worsening toxicity.
- **Drug interaction**: Clarithromycin inhibits P-glycoprotein, which normally pumps digoxin out of cells and into the gut lumen. Inhibition increases digoxin absorption and tissue concentrations.
- **Digibind mechanism**: Fab fragments bind free digoxin, preventing it from binding to the Na+/K+-ATPase. The bound complex is renally excreted.

---

## Case 2: Beta-Blocker Overdose - Cardiogenic Shock

### Clinical Image
![Beta-Blocker Overdose](case_01_image.jpg)
*Source: Clinical illustration of beta-blocker poisoning management - Educational use*

### Patient Presentation
A 52-year-old man with a history of depression is found unresponsive by his wife. Empty bottles of metoprolol succinate (extended-release) and propranolol are found nearby. EMS reports initial heart rate of 38 bpm and blood pressure of 72/40 mmHg. He was intubated in the field for airway protection.

### Demographics
- Age: 52 years
- Sex: Male
- Past Medical History: Depression, hypertension, type 2 diabetes
- Medications: Metoprolol succinate 100 mg daily, lisinopril 20 mg daily, metformin
- Suspected ingestion: ~50 tablets of metoprolol ER, ~30 tablets of propranolol

### Chief Complaint
Found unresponsive with empty medication bottles

### Physical Examination
- Blood pressure: 68/38 mmHg (on norepinephrine infusion started by EMS)
- Heart rate: 34 bpm
- Temperature: 35.8°C (hypothermic)
- Pupils: 3 mm, reactive
- Cardiovascular: Bradycardic, weak peripheral pulses
- Lungs: Intubated, clear on auscultation
- Extremities: Cool, mottled

### Workup
- Point-of-care glucose: 52 mg/dL (hypoglycemic)
- ECG: Sinus bradycardia with first-degree AV block, QRS 110 ms
- ABG: pH 7.22, PCO2 32, PaO2 280 (on 100% FiO2), lactate 6.8 mmol/L
- Basic metabolic panel: Na 138, K 5.2, Cr 1.4, glucose 54
- Echocardiography: Severely reduced LV function (EF 15%), diffuse hypokinesis
- Toxicology screen: Negative for coingestants

### Diagnosis
Severe Beta-Blocker Toxicity with Cardiogenic Shock

### Treatment
1. **Supportive care**: IV fluids, vasopressors (norepinephrine, epinephrine)
2. **Glucagon**: 5 mg IV bolus, then 2-5 mg/hour infusion
   - Bypasses beta-receptor to activate adenylyl cyclase via glucagon receptor
3. **High-dose insulin euglycemia therapy (HIET)**:
   - Regular insulin 1 unit/kg bolus, then 1-10 units/kg/hour
   - Dextrose infusion to maintain glucose 100-250 mg/dL
   - Potassium supplementation as needed
4. Calcium chloride (or gluconate) for inotropy
5. Atropine for bradycardia (often ineffective in severe toxicity)
6. Consider temporary transvenous pacing if refractory bradycardia
7. Lipid emulsion therapy if refractory shock
8. ECMO consideration for refractory cardiogenic shock
9. Decontamination: Whole bowel irrigation for extended-release formulation
10. Psychiatry consultation after medical stabilization

### Physiological Principles Demonstrated
- **Beta-receptor blockade effects**: Beta-1 blockade reduces heart rate (negative chronotropy) and contractility (negative inotropy). Beta-2 blockade can cause bronchospasm and hypoglycemia (blocks glycogenolysis and gluconeogenesis).
- **Glucagon mechanism**: Glucagon activates adenylyl cyclase via the glucagon receptor, bypassing the blocked beta-receptors to increase cAMP and improve cardiac contractility.
- **High-dose insulin mechanism**: Insulin improves cardiac metabolism by promoting glucose uptake and utilization in the stressed myocardium, improving contractility independent of beta-receptors.
- **Extended-release considerations**: Metoprolol ER releases drug over 24 hours; toxicity may be prolonged and delayed, requiring extended monitoring and treatment.

---

## Case 3: Warfarin Reversal - Anticoagulation Emergency

### Clinical Image
![Warfarin Bleeding Complications](case_01_image.jpg)
*Source: [Wikimedia Commons - Warfarin mechanism](https://commons.wikimedia.org/wiki/File:Warfarin_clotting_factor_synthesis_inhibition.svg) - CC BY-SA 4.0*

### Patient Presentation
A 72-year-old man on warfarin for atrial fibrillation falls at home and strikes his head on the floor. He is brought to the emergency department by ambulance after his wife found him confused with a large scalp laceration. He took his warfarin dose this morning and cannot recall how much.

### Demographics
- Age: 72 years
- Sex: Male
- Past Medical History: Atrial fibrillation, mechanical mitral valve replacement (5 years ago), hypertension
- Medications: Warfarin 7.5 mg daily (target INR 2.5-3.5 for mechanical valve), lisinopril, metoprolol

### Chief Complaint
Fall with head trauma and confusion

### Physical Examination
- Blood pressure: 168/92 mmHg
- Heart rate: 82 bpm (irregularly irregular)
- GCS: 13 (E3V4M6)
- General: Confused, large scalp laceration with active bleeding
- Pupils: Left 4 mm, right 3 mm, both reactive but sluggish
- Cardiovascular: Irregular rhythm, mechanical click audible
- Neurological: Left-sided weakness (right hemiparesis), difficulty speaking

### Workup
- INR: 4.8 (supratherapeutic)
- PT: 52 seconds
- Hemoglobin: 10.2 g/dL
- Platelet count: 178,000/μL
- CT head (non-contrast): Right-sided acute subdural hematoma with 8 mm midline shift

### Diagnosis
Traumatic Intracranial Hemorrhage (Subdural Hematoma) in setting of Supratherapeutic Anticoagulation

### Treatment
1. **Emergent INR reversal**:
   - **4-Factor Prothrombin Complex Concentrate (4F-PCC)** 50 units/kg IV
   - Preferred over FFP for speed and volume
   - Repeat INR in 15-30 minutes (target INR <1.5)
2. **Vitamin K** 10 mg IV (slow infusion to prevent anaphylaxis)
   - Works over 6-24 hours; PCC provides immediate reversal
3. Neurosurgery consultation for potential surgical evacuation
4. Blood pressure control (target SBP <140 mmHg)
5. Avoid antiplatelet agents
6. Post-stabilization: Discuss long-term anticoagulation strategy given mechanical valve (cannot remain off anticoagulation indefinitely)
7. Home safety evaluation before discharge

### Physiological Principles Demonstrated
- **Warfarin mechanism**: Warfarin inhibits vitamin K epoxide reductase (VKORC1), preventing recycling of vitamin K. This impairs hepatic synthesis of factors II, VII, IX, and X (and proteins C and S).
- **Factor half-lives**: Factor VII has the shortest half-life (~6 hours), so PT/INR rises first. Full anticoagulant effect takes 3-5 days as all factors decline.
- **4F-PCC vs. FFP**: 4F-PCC provides concentrated clotting factors (II, VII, IX, X) in small volume with rapid administration. FFP requires large volumes, thawing time, and risks volume overload.
- **Vitamin K importance**: PCC provides temporary factor replacement; vitamin K is needed to restore hepatic synthesis of clotting factors for sustained reversal.
- **Mechanical valve considerations**: Mechanical valves have high thrombotic risk without anticoagulation. After stabilization, anticoagulation must be resumed, often with bridging strategies.